在CYP2C19基因分型的健康受试者中，增加氯吡格雷维持剂量或联合使用兰索拉唑对氯吡格雷抗血小板反应的影响。 - Suppr

Suppr

超能文献

Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects.

作者信息

Hulot J-S, Wuerzner G, Bachelot-Loza C, Azizi M, Blanchard A, Peyrard S, Funck-Brentano C, Gaussem P

出版信息

J Thromb Haemost. 2010 Mar;8(3):610-3. doi: 10.1111/j.1538-7836.2009.03729.x. Epub 2009 Dec 21.

DOI:10.1111/j.1538-7836.2009.03729.x

PMID:20040040

Abstract

摘要

相似文献

Effect of an increased clopidogrel maintenance dose or lansoprazole co-administration on the antiplatelet response to clopidogrel in CYP2C19-genotyped healthy subjects.

J Thromb Haemost. 2010 Mar;8(3):610-3. doi: 10.1111/j.1538-7836.2009.03729.x. Epub 2009 Dec 21.

Drug-drug interaction of rabeprazole and clopidogrel in healthy Chinese volunteers.

Eur J Clin Pharmacol. 2013 Feb;69(2):179-87. doi: 10.1007/s00228-012-1329-z. Epub 2012 Jun 16.

Clopidogrel pharmacokinetics and pharmacodynamics vary widely despite exclusion or control of polymorphisms (CYP2C19, ABCB1, PON1), noncompliance, diet, smoking, co-medications (including proton pump inhibitors), and pre-existent variability in platelet function.

J Am Coll Cardiol. 2013 Feb 26;61(8):872-9. doi: 10.1016/j.jacc.2012.11.040. Epub 2013 Jan 16.

[Efficacy and safety of concomitant use of rabeprazole during dual-antiplatelet therapy with clopidogrel and aspirin after drug-eluting stent implantation: a retrospective cohort study].

Yakugaku Zasshi. 2010 Dec;130(12):1743-50. doi: 10.1248/yakushi.130.1743.

Interaction between clopidogrel and proton pump inhibitors: hypothesis to explain multifactorial CYP2C19 inhibition.

Drug Metab Lett. 2009 Dec;3(4):287-9. doi: 10.2174/187231209790218136.

Pharmacogenetic testing for clopidogrel using the rapid INFINITI analyzer: a dose-escalation study.

JACC Cardiovasc Interv. 2009 Nov;2(11):1095-101. doi: 10.1016/j.jcin.2009.08.018.

High doses of clopidogrel to overcome genetic resistance: the randomized crossover CLOVIS-2 (Clopidogrel and Response Variability Investigation Study 2).

JACC Cardiovasc Interv. 2011 Apr;4(4):392-402. doi: 10.1016/j.jcin.2011.03.002.

The worry about clopidogrel "nonresponsiveness": identification and treatment in the post-percutaneous coronary intervention patient.

JACC Cardiovasc Interv. 2009 Nov;2(11):1102-4. doi: 10.1016/j.jcin.2009.09.005.

Effects of rabeprazole on the antiplatelet effects and pharmacokinetics of clopidogrel in healthy volunteers.

Arch Cardiovasc Dis. 2013 Dec;106(12):661-71. doi: 10.1016/j.acvd.2013.09.002. Epub 2013 Nov 15.

Genetic polymorphisms of CYP2C19 influences the response to clopidogrel in ischemic heart disease patients in the South Indian Tamilian population.

Eur J Clin Pharmacol. 2013 Mar;69(3):415-22. doi: 10.1007/s00228-012-1381-8. Epub 2012 Sep 6.

引用本文的文献

Antiplatelet Therapy for Atherothrombotic Disease in 2022-From Population to Patient-Centered Approaches.

Front Cardiovasc Med. 2022 Jan 28;9:805525. doi: 10.3389/fcvm.2022.805525. eCollection 2022.

Prevalence of CYP2C19 and ITGB3 polymorphisms among Bangladeshi patients who underwent percutaneous coronary intervention.

SAGE Open Med. 2021 Aug 26;9:20503121211042209. doi: 10.1177/20503121211042209. eCollection 2021.

Clopidogrel utilization in patients with coronary artery disease and diabetes mellitus: should we determine CYP2C19*2 genotype?

Eur J Clin Pharmacol. 2018 Dec;74(12):1567-1574. doi: 10.1007/s00228-018-2530-5. Epub 2018 Aug 3.

Omeprazole, pantoprazole, and CYP2C19 effects on clopidogrel pharmacokinetic-pharmacodynamic relationships in stable coronary artery disease patients.

Eur J Clin Pharmacol. 2015 Sep;71(9):1059-66. doi: 10.1007/s00228-015-1882-3. Epub 2015 Jun 14.

Clinical pharmacokinetics and pharmacodynamics of clopidogrel.

Clin Pharmacokinet. 2015 Feb;54(2):147-66. doi: 10.1007/s40262-014-0230-6.

Prasugrel but not high dose clopidogrel overcomes the lansoprazole neutralizing effect of P2Y12 inhibition: Results of the randomized DOSAPI study.

Eur J Clin Pharmacol. 2014 Sep;70(9):1049-57. doi: 10.1007/s00228-014-1710-1. Epub 2014 Jul 12.

Clinical outcomes associated with proton pump inhibitor use among clopidogrel-treated patients within CYP2C19 genotype groups following acute myocardial infarction.

Pharmacogenomics J. 2015 Feb;15(1):20-5. doi: 10.1038/tpj.2014.28. Epub 2014 Jul 8.

Antiplatelet drug interactions with proton pump inhibitors.

Expert Opin Drug Metab Toxicol. 2014 Feb;10(2):175-89. doi: 10.1517/17425255.2014.856883. Epub 2013 Nov 9.

Influence of genetic variations on levels of inflammatory markers of healthy subjects at baseline and one week after clopidogrel therapy; results of a preliminary study.

Int J Mol Sci. 2013 Aug 8;14(8):16402-13. doi: 10.3390/ijms140816402.

Clopidogrel and PPI interaction: clinically relevant or not?

Curr Cardiol Rep. 2012 Feb;14(1):49-58. doi: 10.1007/s11886-011-0233-y.

文献AI研究员

20分钟写一篇综述，助力文献阅读效率提升50倍。

立即体验

用中文搜PubMed

大模型驱动的PubMed中文搜索引擎

马上搜索

文档翻译

学术文献翻译模型，支持多种主流文档格式。

立即体验